Travere Therapeutics’ (TVTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Travere Therapeutics (NASDAQ:TVTX) in a report released on Tuesday morning,Benzinga reports. HC Wainwright currently has a $30.00 target price on the stock. HC Wainwright also issued estimates for Travere Therapeutics’ Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.62) EPS, FY2025 earnings at ($2.30) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at ($0.17) EPS, FY2028 earnings at $0.13 EPS and FY2029 earnings at $0.47 EPS.

A number of other research firms have also recently commented on TVTX. Bank of America raised their price target on Travere Therapeutics from $29.00 to $31.00 and gave the company a “buy” rating in a report on Tuesday, April 1st. Guggenheim reiterated a “buy” rating and set a $47.00 target price on shares of Travere Therapeutics in a research report on Monday, April 14th. Stifel Nicolaus boosted their price target on Travere Therapeutics from $22.00 to $23.00 and gave the stock a “hold” rating in a report on Friday, May 2nd. Cantor Fitzgerald restated an “overweight” rating on shares of Travere Therapeutics in a research note on Wednesday, April 23rd. Finally, Scotiabank reaffirmed an “outperform” rating on shares of Travere Therapeutics in a report on Friday, April 11th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $32.14.

Travere Therapeutics Trading Up 1.1%

Travere Therapeutics stock opened at $15.00 on Tuesday. Travere Therapeutics has a 12-month low of $7.72 and a 12-month high of $25.29. The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of -5.34 and a beta of 0.72. The firm has a 50 day moving average of $16.79 and a 200 day moving average of $18.14. The company has a current ratio of 2.05, a quick ratio of 2.03 and a debt-to-equity ratio of 9.46.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.08. The business had revenue of $81.73 million during the quarter, compared to analyst estimates of $77.44 million. Travere Therapeutics had a negative net margin of 82.88% and a negative return on equity of 1,179.73%. The company’s revenue was up 83.3% on a year-over-year basis. During the same period in the prior year, the business posted ($1.76) earnings per share. As a group, research analysts predict that Travere Therapeutics will post -1.4 earnings per share for the current year.

Insider Activity at Travere Therapeutics

In related news, CEO Eric M. Dube sold 18,924 shares of the stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $21.05, for a total value of $398,350.20. Following the completion of the transaction, the chief executive officer owned 419,173 shares of the company’s stock, valued at approximately $8,823,591.65. This trade represents a 4.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Christopher R. Cline sold 1,784 shares of Travere Therapeutics stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $21.05, for a total value of $37,553.20. Following the completion of the transaction, the chief financial officer owned 93,126 shares of the company’s stock, valued at approximately $1,960,302.30. This represents a 1.88% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 23,342 shares of company stock valued at $485,753 over the last 90 days. 4.19% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Travere Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Driehaus Capital Management LLC increased its position in shares of Travere Therapeutics by 608.1% during the 4th quarter. Driehaus Capital Management LLC now owns 2,217,975 shares of the company’s stock valued at $38,637,000 after purchasing an additional 1,904,733 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its position in Travere Therapeutics by 479.9% in the first quarter. Adage Capital Partners GP L.L.C. now owns 2,184,898 shares of the company’s stock worth $39,153,000 after buying an additional 1,808,098 shares during the last quarter. Armistice Capital LLC boosted its stake in Travere Therapeutics by 20.6% during the first quarter. Armistice Capital LLC now owns 8,872,000 shares of the company’s stock worth $158,986,000 after buying an additional 1,514,000 shares during the period. BNP Paribas Financial Markets purchased a new position in Travere Therapeutics during the fourth quarter worth $21,075,000. Finally, Nuveen LLC bought a new position in Travere Therapeutics during the first quarter valued at $21,569,000.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.